Latest Boehringer Ingelheim Stories
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Significant portion of alliance opportunity will remain unchanged; some countries will transition to exclusive promotion in 2015 INDIANAPOLIS and INGELHEIM, Germany, Oct.
LONDON and BOSTON, October 28, 2014 /PRNewswire/ -- Global top 20 pharma company streamlines R&D IT with cross-domain platform Boehringer Ingelheim,
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct.
BONN, Germany, October 14, 2014 /PRNewswire/ -- Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer
RIDGEFIELD, Conn., Oct.
Case Funding Company says recent $650MM settlement of approximately 4K filed cases in both state and federal courts over blood thinner, amounts to an average Pradaxa settlement amount or settlement
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.